{"id":"W2147881986","doi":"10.1186/1756-8722-5-67","title":"Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial","year":2012,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"Takeda Oncology; European Society for Medical Oncology; National Comprehensive Cancer Network","keywords":"Rituximab; Medicine; Bortezomib; Internal medicine; Follicular lymphoma; International Prognostic Index; Hazard ratio; Lymphoma; Clinical endpoint; Oncology; Surgery; Randomized controlled trial; Confidence interval; Multiple myeloma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002951396,0.0007834571,0.01076938,0.002136573,0.0001665785,0.00002258192,0.000316856,0.0008635553,0.0002431913],"category_scores_gemma":[0.002236746,0.0005095112,0.001834295,0.00159184,0.0008626358,0.0004402644,0.0001272059,0.0006659273,0.00004604172],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001989473,"about_ca_system_score_gemma":0.001551015,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008586015,"about_ca_topic_score_gemma":0.0005771228,"domain_scores_codex":[0.9915435,0.00209984,0.003492162,0.0006498077,0.001052986,0.001161691],"domain_scores_gemma":[0.9886702,0.004714754,0.004139673,0.0007155295,0.001121646,0.0006382202],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8332009,0.0945292,0.04310078,0.00006998133,0.02069693,0.003558871,0.0009312188,0.0000176802,0.000008284364,0.0009451435,0.0004505872,0.002490403],"study_design_scores_gemma":[0.9188962,0.01744408,0.02286078,0.0001937685,0.03726924,0.001061283,0.0004649872,0.0001885367,0.0006252129,0.00005071582,0.0005328034,0.0004124114],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9917402,0.002805357,0.0003201909,0.0007062798,0.001537083,0.002491795,0.000107807,0.00003127785,0.0002599704],"genre_scores_gemma":[0.9933043,0.00062873,0.005039078,0.000275655,0.0002990381,0.0001967021,0.0001602478,0.00006912028,0.00002719115],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08569527,"threshold_uncertainty_score":0.9997357,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01518842291036072,"score_gpt":0.3100544583008139,"score_spread":0.2948660353904531,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}